Apolipoprotein B Identifies Dyslipidemic Phenotypes in Normocholesterolemic Type 2 Diabetic Patients

This cross-sectional clinical study enrolled 100 type 2 diabetic patients and examined ApoB concentrations among those with normal LDL-C — asking whether ApoB measurement identifies atherogenic dyslipidemia that LDL-C misses in this clinically important population.

Among 75 patients classified as normocholesterolemic (normal LDL-C), 45% had elevated ApoB (>110 mg/dL), meeting criteria for hyperapobetalipoproteinemia. This subgroup showed a substantially more atherogenic metabolic profile: higher triglycerides, lower HDL-C, and increased prevalence of small dense LDL particles compared with normocholesterolemic diabetics with normal ApoB. LDL-C alone correctly classified only 55% of the normocholesterolemic diabetic patients by atherogenic risk.

The clinical significance of this finding is high because diabetic dyslipidemia is defined by elevated triglycerides, low HDL-C, and small dense LDL — the metabolic pattern that produces the greatest discordance between LDL-C and ApoB. Type 2 diabetes substantially raises cardiovascular risk through multiple mechanisms beyond LDL-C, and this study demonstrates that standard lipid testing misses the dominant atherogenic pattern in nearly half of normocholesterolemic diabetic patients.

The practical implication: ApoB measurement in type 2 diabetic patients — particularly those with apparently normal LDL-C — identifies a high-risk phenotype that would otherwise be undertreated by guidelines anchored to LDL-C thresholds.

We rate the evidence moderate. A well-characterized cross-sectional study demonstrating that ApoB measurement identifies elevated atherogenic particle burden in 45% of normocholesterolemic type 2 diabetic patients missed by LDL-C — providing an early clinical demonstration of diabetic dyslipidemia’s ApoB-LDL-C discordance.